Diversified Trust Co Reduces Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Diversified Trust Co cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.2% in the fourth quarter, HoldingsChannel reports. The firm owned 2,481 shares of the biopharmaceutical company’s stock after selling 749 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after buying an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Alnylam Pharmaceuticals by 3.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after purchasing an additional 16,756 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after purchasing an additional 100,000 shares during the period. Swiss National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 25.7% in the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after acquiring an additional 63,385 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ ALNY opened at $237.98 on Friday. The firm’s 50-day moving average is $249.60 and its two-hundred day moving average is $259.41. The company has a market capitalization of $30.69 billion, a PE ratio of -90.83 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the previous year, the business posted $1.15 EPS. The business’s revenue was down 33.3% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,752 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the completion of the transaction, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,122 shares of company stock valued at $2,540,455 over the last quarter. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Chardan Capital restated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.